Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli

The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a simila...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2023-10, Vol.67 (10), p.e0054723-e0054723
Hauptverfasser: Le Terrier, Christophe, Nordmann, Patrice, Bouvier, Maxime, Poirel, Laurent
Format: Artikel
Sprache:eng
Schlagworte:
Experimental Therapeutics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e0054723
container_issue 10
container_start_page e0054723
container_title Antimicrobial agents and chemotherapy
container_volume 67
creator Le Terrier, Christophe
Nordmann, Patrice
Bouvier, Maxime
Poirel, Laurent
description The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli , including metallo-β-lactamase producers.
doi_str_mv 10.1128/aac.00547-23
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10583657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2861303261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-b3f1667c451073775e853ef25f0341a207ea87ce72be366d0c9b383d25c8b503</originalsourceid><addsrcrecordid>eNpVUktuFDEUtBCIDAM7DuBlkNKJP223Z4VQFCBSJDbZW89uN23UbXdsd1CulYNwDa6BMzNCycauZ7-qenoqhD5Sck4pUxcA9pwQ0XYN46_QhpKdaqTYyddoQ4iUTatIe4Le5fyL1FrsyFt0wjspFVdig_5ezwvYguOAwd6tPrkemxShb_LibEnrjP88NlNtgRmyyzgGnNds3VK88ZMvD7hEHBNMeHHBzfnCQjJwwPi0OOP3-KyypniEEHo8QDqUnzBMMbiqgX3ANs7GByi--vz2ZcRw783efc8qELyJ6fjyfLJKHutEJab8pHOV7eiSt6OHqjn59-jNAFN2H473Ft1-vbq9_N7c_Ph2ffnlprFM0dIYPlApO9sKSjredcIpwd3AxEB4S4GRzoHqrOuYcVzKntid4Yr3TFhlBOFb9Pkgu6xmdr11odTV6CX5GdKDjuD1y5_gR_0z3mtKhOJSdFXh9KiQ4t3qctGzr-ueJggurlkzJSknnNVzi84OrTbFnJMb_vtQop-yoWs29D4bmnH-D76ks7E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2861303261</pqid></control><display><type>article</type><title>Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Le Terrier, Christophe ; Nordmann, Patrice ; Bouvier, Maxime ; Poirel, Laurent</creator><contributor>de Jonge, Boudewijn L.</contributor><creatorcontrib>Le Terrier, Christophe ; Nordmann, Patrice ; Bouvier, Maxime ; Poirel, Laurent ; de Jonge, Boudewijn L.</creatorcontrib><description>The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli , including metallo-β-lactamase producers.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/aac.00547-23</identifier><identifier>PMID: 37668385</identifier><language>eng</language><publisher>1752 N St., N.W., Washington, DC: American Society for Microbiology</publisher><subject>Experimental Therapeutics</subject><ispartof>Antimicrobial agents and chemotherapy, 2023-10, Vol.67 (10), p.e0054723-e0054723</ispartof><rights>Copyright © 2023 American Society for Microbiology. 2023 American Society for Microbiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c281t-b3f1667c451073775e853ef25f0341a207ea87ce72be366d0c9b383d25c8b503</cites><orcidid>0000-0002-5455-5576</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583657/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583657/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><contributor>de Jonge, Boudewijn L.</contributor><creatorcontrib>Le Terrier, Christophe</creatorcontrib><creatorcontrib>Nordmann, Patrice</creatorcontrib><creatorcontrib>Bouvier, Maxime</creatorcontrib><creatorcontrib>Poirel, Laurent</creatorcontrib><title>Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli</title><title>Antimicrobial agents and chemotherapy</title><description>The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli , including metallo-β-lactamase producers.</description><subject>Experimental Therapeutics</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUktuFDEUtBCIDAM7DuBlkNKJP223Z4VQFCBSJDbZW89uN23UbXdsd1CulYNwDa6BMzNCycauZ7-qenoqhD5Sck4pUxcA9pwQ0XYN46_QhpKdaqTYyddoQ4iUTatIe4Le5fyL1FrsyFt0wjspFVdig_5ezwvYguOAwd6tPrkemxShb_LibEnrjP88NlNtgRmyyzgGnNds3VK88ZMvD7hEHBNMeHHBzfnCQjJwwPi0OOP3-KyypniEEHo8QDqUnzBMMbiqgX3ANs7GByi--vz2ZcRw783efc8qELyJ6fjyfLJKHutEJab8pHOV7eiSt6OHqjn59-jNAFN2H473Ft1-vbq9_N7c_Ph2ffnlprFM0dIYPlApO9sKSjredcIpwd3AxEB4S4GRzoHqrOuYcVzKntid4Yr3TFhlBOFb9Pkgu6xmdr11odTV6CX5GdKDjuD1y5_gR_0z3mtKhOJSdFXh9KiQ4t3qctGzr-ueJggurlkzJSknnNVzi84OrTbFnJMb_vtQop-yoWs29D4bmnH-D76ks7E</recordid><startdate>20231018</startdate><enddate>20231018</enddate><creator>Le Terrier, Christophe</creator><creator>Nordmann, Patrice</creator><creator>Bouvier, Maxime</creator><creator>Poirel, Laurent</creator><general>American Society for Microbiology</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5455-5576</orcidid></search><sort><creationdate>20231018</creationdate><title>Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli</title><author>Le Terrier, Christophe ; Nordmann, Patrice ; Bouvier, Maxime ; Poirel, Laurent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-b3f1667c451073775e853ef25f0341a207ea87ce72be366d0c9b383d25c8b503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Experimental Therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le Terrier, Christophe</creatorcontrib><creatorcontrib>Nordmann, Patrice</creatorcontrib><creatorcontrib>Bouvier, Maxime</creatorcontrib><creatorcontrib>Poirel, Laurent</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le Terrier, Christophe</au><au>Nordmann, Patrice</au><au>Bouvier, Maxime</au><au>Poirel, Laurent</au><au>de Jonge, Boudewijn L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><date>2023-10-18</date><risdate>2023</risdate><volume>67</volume><issue>10</issue><spage>e0054723</spage><epage>e0054723</epage><pages>e0054723-e0054723</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against E. coli producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant E. coli , including metallo-β-lactamase producers.</abstract><cop>1752 N St., N.W., Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>37668385</pmid><doi>10.1128/aac.00547-23</doi><orcidid>https://orcid.org/0000-0002-5455-5576</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2023-10, Vol.67 (10), p.e0054723-e0054723
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10583657
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Experimental Therapeutics
title Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in Escherichia coli
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20acquired%20broad-spectrum%20%CE%B2-lactamases%20on%20susceptibility%20to%20oral%20penems/carbapenems%20(tebipenem,%20sulopenem,%20and%20faropenem)%20alone%20or%20in%20combination%20with%20avibactam%20and%20taniborbactam%20%CE%B2-lactamase%20inhibitors%20in%20Escherichia%20coli&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Le%20Terrier,%20Christophe&rft.date=2023-10-18&rft.volume=67&rft.issue=10&rft.spage=e0054723&rft.epage=e0054723&rft.pages=e0054723-e0054723&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/aac.00547-23&rft_dat=%3Cproquest_pubme%3E2861303261%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2861303261&rft_id=info:pmid/37668385&rfr_iscdi=true